{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-001016","form_type":"8-K","ticker":"CBIO","cik":"0001253689","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2025-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.145910+00:00","generated_at":"2026-05-26T19:24:21.078364+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.7,"confidence":"high","headline":"GlycoMimetics amends merger; $200M financing now pre-closing Crescent securities","bullets":["Ownership split unchanged: GLYC holders ~3.10%, Crescent ~96.90% after close.","Exchange ratio ~14.9149 Crescent shares per GLYC share; based on Sep 30 caps.","A&R Purchase Agreement: $200M Crescent securities purchased pre-closing, replacing post-closing GLYC financing.","Amendment adjusts filings; S-4 registration statement and company stockholder approval sequence updated.","Condition: GLYC net cash at closing must be ~$1.8M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-001016","json":"https://secwatch.observer/filing/0001558370-25-001016.json","markdown":"https://secwatch.observer/filing/0001558370-25-001016.md","text":"https://secwatch.observer/filing/0001558370-25-001016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1253689/000155837025001016/0001558370-25-001016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1253689/000155837025001016/glyc-20250214x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T19:24:21.078364+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}